Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #20       Takeda licenses seven CNS programs to Neurocrine.       In recent years many large biopharmaceutical companies have stopped their R&D efforts in the neuroscience domain. The decision to halt investments is true across the entire spectrum […]

  Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #20.19       Mpro: A potential antiviral target for a SARS-CoV-2       The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is slowly decreasing in many countries around the world, in spite of the lack of efficient treatments. Unprecedented […]